Seek Returns logo

INSM vs. REGN: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at INSM and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolINSMREGN
Company NameInsmed IncorporatedRegeneron Pharmaceuticals, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryBiotechnologyBiotechnology
Market Capitalization42.39 billion USD80.12 billion USD
ExchangeNasdaqGSNasdaqGS
Listing DateJune 1, 2000April 2, 1991
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of INSM and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

INSM vs. REGN: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolINSMREGN
5-Day Price Return3.32%6.27%
13-Week Price Return50.56%23.21%
26-Week Price Return194.11%23.55%
52-Week Price Return170.81%-1.02%
Month-to-Date Return5.30%13.07%
Year-to-Date Return189.17%3.46%
10-Day Avg. Volume2.06M1.24M
3-Month Avg. Volume2.36M1.06M
3-Month Volatility43.07%39.06%
Beta1.050.34

Profitability

Return on Equity (TTM)

INSM

-183.55%

Biotechnology Industry

Max
96.19%
Q3
12.45%
Median
-16.39%
Q1
-47.43%
Min
-131.19%

INSM has a negative Return on Equity of -183.55%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

REGN

15.31%

Biotechnology Industry

Max
96.19%
Q3
12.45%
Median
-16.39%
Q1
-47.43%
Min
-131.19%

In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.31% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

INSM vs. REGN: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

INSM

-264.83%

Biotechnology Industry

Max
84.13%
Q3
19.34%
Median
-1.39%
Q1
-117.64%
Min
-296.77%

INSM has a negative Net Profit Margin of -264.83%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

REGN

32.13%

Biotechnology Industry

Max
84.13%
Q3
19.34%
Median
-1.39%
Q1
-117.64%
Min
-296.77%

A Net Profit Margin of 32.13% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

INSM vs. REGN: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

INSM

-258.92%

Biotechnology Industry

Max
78.85%
Q3
20.86%
Median
0.51%
Q1
-128.29%
Min
-315.84%

INSM has a negative Operating Profit Margin of -258.92%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

REGN

25.89%

Biotechnology Industry

Max
78.85%
Q3
20.86%
Median
0.51%
Q1
-128.29%
Min
-315.84%

An Operating Profit Margin of 25.89% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

INSM vs. REGN: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

SymbolINSMREGN
Return on Equity (TTM)-183.55%15.31%
Return on Assets (TTM)-54.63%11.91%
Net Profit Margin (TTM)-264.83%32.13%
Operating Profit Margin (TTM)-258.92%25.89%
Gross Profit Margin (TTM)76.54%86.28%

Financial Strength

Current Ratio (MRQ)

INSM

4.63

Biotechnology Industry

Max
15.83
Q3
7.97
Median
4.06
Q1
2.64
Min
0.72

INSM’s Current Ratio of 4.63 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

REGN

4.06

Biotechnology Industry

Max
15.83
Q3
7.97
Median
4.06
Q1
2.64
Min
0.72

REGN’s Current Ratio of 4.06 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

INSM vs. REGN: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

INSM

0.77

Biotechnology Industry

Max
1.27
Q3
0.62
Median
0.13
Q1
0.00
Min
0.00

INSM’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.77. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

REGN

0.09

Biotechnology Industry

Max
1.27
Q3
0.62
Median
0.13
Q1
0.00
Min
0.00

REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

INSM vs. REGN: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

INSM

-27.79

Biotechnology Industry

Max
72.37
Q3
1.71
Median
-15.18
Q1
-65.75
Min
-166.46

INSM has a negative Interest Coverage Ratio of -27.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

REGN

49.98

Biotechnology Industry

Max
72.37
Q3
1.71
Median
-15.18
Q1
-65.75
Min
-166.46

REGN’s Interest Coverage Ratio of 49.98 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

INSM vs. REGN: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

SymbolINSMREGN
Current Ratio (MRQ)4.634.06
Quick Ratio (MRQ)4.183.38
Debt-to-Equity Ratio (MRQ)0.770.09
Interest Coverage Ratio (TTM)-27.7949.98

Growth

Revenue Growth

INSM vs. REGN: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

INSM vs. REGN: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

INSM

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INSM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

REGN

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

INSM vs. REGN: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

INSM

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INSM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

REGN

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

INSM vs. REGN: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

SymbolINSMREGN
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

INSM

--

Biotechnology Industry

Max
115.91
Q3
56.76
Median
21.80
Q1
15.79
Min
4.51

P/E Ratio data for INSM is currently unavailable.

REGN

16.92

Biotechnology Industry

Max
115.91
Q3
56.76
Median
21.80
Q1
15.79
Min
4.51

REGN’s P/E Ratio of 16.92 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

INSM vs. REGN: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

INSM

93.64

Biotechnology Industry

Max
58.56
Q3
29.31
Median
8.30
Q1
4.89
Min
0.86

With a P/S Ratio of 93.64, INSM trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

REGN

5.44

Biotechnology Industry

Max
58.56
Q3
29.31
Median
8.30
Q1
4.89
Min
0.86

REGN’s P/S Ratio of 5.44 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

INSM vs. REGN: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

INSM

32.19

Biotechnology Industry

Max
17.92
Q3
10.38
Median
4.78
Q1
2.85
Min
0.78

At 32.19, INSM’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

REGN

1.93

Biotechnology Industry

Max
17.92
Q3
10.38
Median
4.78
Q1
2.85
Min
0.78

REGN’s P/B Ratio of 1.93 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

INSM vs. REGN: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

SymbolINSMREGN
Price-to-Earnings Ratio (TTM)--16.92
Price-to-Sales Ratio (TTM)93.645.44
Price-to-Book Ratio (MRQ)32.191.93
Price-to-Free Cash Flow Ratio (TTM)--19.96